Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Brazil, Austria, the Netherlands and Sri Lanka.
These agreements bring the total international coverage to 39 countries, representing a combined population of more than three billion people.
To quote Steve Lisi, "We are encouraged by the rapid expansion of LungFit PH’s international footprint over the past nine months. With access to 39 countries outside of the United States, including key markets such as Japan, Brazil, Mexico, Germany and France, the foundation for significant market share gains is in place.
“While regulatory approvals in some countries will take time, others will begin to benefit from the unique features of LungFit PH in calendar 2026. We look forward to bringing the benefits of LungFit PH to the majority of the world’s hospitals over the next several years.”
Beyond Air's LungFit PH generates nitric oxide from ambient air, eliminating the need for traditional high-pressure cylinders. This tankless technology streamlines hospital operations, enhances efficiency and reduces environmental impact within hospital settings.
XAIR shares jumped 3.2 cents, or 3.5%, to begin trading Wednesday at 95 cents.
Related Stories
